Portfolio Manager Factsheet

February 2019

Shares’ of Spark appreciated after the announcement of the company’s acquisition by Roche at a 122% premium.  Neurocrine was weak after the company announced a collaboration with Voyager Therapeutics for their neurology gene therapy programs, which was associated with higher than expected expense guidance.

Read more »

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.